• Investing
  • Stock
Round Table Thoughts
  • Economy
  • Editor’s Pick
Home Investing ‘There is a lot that’s underestimated at Biogen’: CEO Viehbacher
Investing

‘There is a lot that’s underestimated at Biogen’: CEO Viehbacher

by January 9, 2023
by January 9, 2023 0 comment
Share
0
FacebookTwitterPinterestWhatsapp

Shares of Biogen Inc (NASDAQ: BIIB) have gained nearly 45% since late September but CEO Christopher Viehbacher says there’s still “a lot that’s underestimated” at Biogen.  

Highlights from CEO’s interview with CNBC

Viehbacher is convinced that the likes of “Lecanemab” and “Zuranolone” will contribute significantly to future growth. Speaking this morning with CNBC’s Meg Tirrell, he noted:

“We’ve got two great products to launch. We have Zuranolone, a novel new antidepressant. One of the first new antidepressants in a couple of decades. So, that’s already exciting. I think both of those products will be quite significant.”

At the end of its latest reported quarter, Biogen had over $5.70 billion in cash, equivalents, and marketable securities that the Chief Executive said was sufficient to drive external growth.

Moving forward, he expects the cost side of things to help with growth as well.

Its Alzheimer drug received accelerated approval

Last week, the Food and Drug Administration (FDA) granted accelerated approval for Lecanemab – the Alzheimer drug that Biogen developed in collaboration with the Japanese Eisai Co.

According to CEO Viehbacher, CMS could start providing coverage for this treatment in the back half of 2023.

I think, to a degree, Alzheimer’s is an underestimated disease when I hear, well, maybe it’s a little memory loss. It’s a devastating fatal disease. And this is the first time we’ve actually seen a product that’s demonstrated benefit.

In a clinical trial, Lecanemab was shown to be effective in slowing cognitive decline by 27% over 18 months as Invezz reported here. Wall Street currently has a consensus “overweight” rating on the biotech stock.

The post ‘There is a lot that’s underestimated at Biogen’: CEO Viehbacher appeared first on Invezz.

You Might Also Like
  • What is yield curve control, and what happened today in Japan?
  • Options Spreads: Put & Call Combination Strategies
  • What Are Cash-Settled Options?
  • Argentina win World Cup but ARG token falls 50%
Share
0
FacebookTwitterPinterestWhatsapp

previous post
Lululemon stock sinks following lowered outlook: buy the dip?
next post
25+ US economy statistics: forecast, trends and facts for 2023

You may also like

Why did Rivian pull the plug on its agreement with...

December 13, 2022

Oak Street Health stock just rallied 30%: explained here

January 10, 2023

Don’t fight US stocks during the Thanksgiving week

November 25, 2022

Options Spreads: Put & Call Combination Strategies

April 19, 2023

Best Options Strategies for Trading Earnings

April 14, 2023

U.S. job market is still very hot: what to expect...

December 2, 2022

Market Chameleon Trial Offer

May 11, 2023

Five Below breaks out. Here is the next target for...

November 25, 2022

WWE stock jumped 20% on Friday: find out more

January 6, 2023

OKX Chain launches Liquid Staking with up to 40% APR

December 20, 2022

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Krispy Kreme stock plunges after doughnut chain pauses McDonald’s rollout, pulls outlook

      May 8, 2025
    • Don’t Buy Robinhood Stock… Until You See This Chart Setup

      May 8, 2025
    • UnitedHealthcare sued by shareholders over reaction to CEO’s killing

      May 8, 2025
    • The Unpredictable Stock Market: How to Make Sense of It

      May 8, 2025
    • AMD CEO calls China a ‘large opportunity’ and warns against strict U.S. chip controls

      May 7, 2025

    Popular Posts

    • 1

      Trump-era China sanctions ended by Biden may be...

      June 27, 2024 2,633 views
    • 2

      Walz’s honeymoon with China gets fresh scrutiny as...

      August 9, 2024 2,339 views
    • 3

      Biden appointee played key role in recruiting Chinese...

      June 25, 2024 2,321 views
    • 4

      Shein’s global ambitions leaves some cybersecurity experts fearful...

      July 10, 2024 2,303 views
    • 5

      Harris VP pick spent years promoting research facility...

      August 29, 2024 2,186 views

    Categories

    • Economy (7,009)
    • Editor's Pick (2,066)
    • Investing (538)
    • Stock (2,530)

    Popular Posts

    • 1

      Trump-era China sanctions ended by Biden may be revived under new House GOP bill

      June 27, 2024
    • 2

      Walz’s honeymoon with China gets fresh scrutiny as Harris camp blasts ‘lying’ critics

      August 9, 2024
    • 3

      Biden appointee played key role in recruiting Chinese businesses to Delaware: ‘Longtime friends’

      June 25, 2024
    • 4

      Shein’s global ambitions leaves some cybersecurity experts fearful of Chinese spy threats

      July 10, 2024
    • 5

      Harris VP pick spent years promoting research facility that collaborated with ‘Chinese military company’

      August 29, 2024

    Latest News

    • Krispy Kreme stock plunges after doughnut chain pauses McDonald’s rollout,...

      May 8, 2025
    • Don’t Buy Robinhood Stock… Until You See This Chart Setup

      May 8, 2025
    • UnitedHealthcare sued by shareholders over reaction to CEO’s killing

      May 8, 2025

    Categories

    • Economy (7,009)
    • Editor's Pick (2,066)
    • Investing (538)
    • Stock (2,530)

    Disclaimer: RoundTableThoughts.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 RoundTableThoughts.com. All Rights Reserved.

    Round Table Thoughts
    • Investing
    • Stock
    Round Table Thoughts
    • Economy
    • Editor’s Pick

    Read alsox

    2022 Inflation statistics: how bad is...

    December 2, 2022

    Core inflation remains high, meaning more...

    December 19, 2022

    AMC CEO forgoes pay raise for...

    December 28, 2022
    Sign In

    Keep me signed in until I sign out

    Forgot your password?

    Password Recovery

    A new password will be emailed to you.

    Have received a new password? Login here